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Abstract 
Diabetic retinopathy (DR) is a leading cause of visual impairment in working age in industrialized countries. 
It is classified as non-proliferative (mild, moderate or severe) and proliferative, with diabetic macular 
oedema potentially developing at any of these stages. The prevalence and incidence of DR increase with 
diabetes duration and worsening of metabolic and blood pressure control. Current approaches to prevent 
and/or treat DR include optimized control of blood glucose and blood pressure and screening for early 
identification of high-risk, although still asymptomatic, retinal lesions. Results from recent clinical trials 
suggest a role for blockers of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and 
angiotensin II receptor blockers) and for fenofibrate in reducing progression and/or inducing regression of 
mild-to-moderate non-proliferative DR. Intravitreal administration of anti-vascular endothelial growth 
factor (VEGF) agents was shown to reduce visual loss in more advanced stages of DR, especially in macular 
oedema. 
 
 
 
Epidemiology and Classification 
 
Diabetic retinopathy (DR) remains a leading cause of visual impairment in working age in industrialized 
countries and can reach its more advanced stages in the almost total absence of symptoms. The prevalence 
of DR is about 70% in patients with type 1 diabetes and 40% among those with type 2, with no differences 
by gender [1]. The prevalence increases with disease duration and practically all patients with type 1 
diabetes develop retinopathy, proliferative in half the cases, within 20 years of the diagnosis. The most 
serious forms of retinopathy, proliferative and macular oedema, occur in 23 and 14% of patients with type 
1 and type 2 diabetes, respectively. At our screening centre in Turin, out of 6857 consecutive patients 
screened in 1992–2003, the prevalence of retinopathy was 39%, of which 19% mild, 11% moderate and 
more severe in the remaining cases. 
 
 
Alterations of retinal capillaries are at the basis of DR and include multiple occlusions, increased 
permeability of the vessel wall and, in the proliferative form, growth of newly formed vessels. Occlusions 
cause areas of ischaemia and focal (microaneurysms) or generalized dilatation of the capillaries. Dilated, 
fragile and hyperpermeable vessels result in microhaemorrhages and leakage of serum and lipoproteins in 
the neuroretina, with the formation of oedema and the so-called hard exudates. Occlusion of vessels may 
result in focal retinal ischaemia, which may be manifested as white-grayish areas with blurred margins, or 
cotton wool spots. The presence of these lesions defines non-proliferative retinopathy, which can be mild, 
moderate or severe, and can develop into two forms at high risk of visual loss: diabetic macular oedema 
(DME) and proliferative diabetic retinopathy (PDR) (figures 1, 2) [2]. 
 
Figure 1. Proliferative retinopathy with tufts of new vessels accompanied by fibroglial tissue departing from the optic disc. There are signs of retinal 
tear and intravitreal bleeding. Some hard exudates in the macular region indicate the presence of macular oedema. 
 
 
 
Figure 2. Diabetic macular edema with thickening of the retina in the macular region and deposition of hard exudates. 
 
 
 
 
When the lesions of DR involve the macula lutea, the part of the retina responsible for vision of colours and 
details, severe functional impairment may result. DME affects primarily patients with type 2 diabetes and, 
as these represent more than 90% of the diabetic population, it is now the main cause of visual impairment 
in diabetes. Progressive ischaemia of the peripheral retina can cause PDR, with growth of new vessels 
which may invade the vitreous and give rise to vitreous haemorrhages and development of fibroglial tissue. 
The latter, by contracting, may cause retinal detachment. Severe ischaemia may proceed to the anterior 
chamber with development of iris neovascularization (rubeosis iridis), causing the terminal condition of 
neovascular glaucoma. 
 
 
Although DR is considered predominantly a pathology of microvessels, increasing evidence points at 
degeneration of the neuroretina (mainly apoptosis of ganglion cells and glial activation) as an early event 
which may predate and perhaps contribute to microcirculatory abnormalities [3–7]. Damage of the 
neuroretina may result in loss of colour discrimination and contrast sensitivity, as detectable by 
electrophysiological studies in patients with short diabetes duration [8–10], and delayed multifocal 
electroretinographic implicit time may predict the development of early microangiopathy [11–13]. 
Metabolic and signalling pathways involved in retinal neurodegeneration may be shared with, and/or 
activate mechanisms involved in, the pathogenesis of microangiopathy [14]. 
 
Pathophysiology 
 
Among the possible mechanisms of glucose-induced vascular damage, potential targets for therapy, four 
hypotheses have been widely entertained: (i) increased flux through the polyol pathway, (ii) increased 
formation of advanced glycation end-products (AGEs), (iii) protein kinase C (PKC) activation, (iv) increased 
flux through the hexosamine pathway. 
 
 
Aldose reductase (AR) is the key enzyme of the polyol pathway. It normally reduces toxic aldehydes to 
inactive alcohols and excess intracellular glucose to sorbitol while consuming NADPH with consequent 
hyperglycaemic pseudohypoxia [15] and increased susceptibility to intracellular oxidative stress [16]. 
However, sorbinil, an AR inhibitor did not modify the course of DR in a clinical trial [17]. 
 
 
Intracellular high glucose reacts with proteins, amino acids and nucleic acids via Schiff base condensation 
with amino groups, followed by irreversible rearrangement into Amadori products. Further Maillard 
reactions slowly produce AGE, which can also derive from earlier glycation products through glycoxidation 
or reactive dicarbonyl fragments generated from free glucose. AGE, in turn, can modify intracellular 
proteins [18], extracellular matrix [19] and circulating proteins, leading to activation of AGE receptors and 
production of inflammatory cytokines and growth factors. Inhibition of AGE by aminoguanidine prevents 
structural changes in experimental DR [20], but has not been tested in humans because of toxicity. 
 
 
Intracellular high glucose increases the de novo synthesis of the lipid second messenger diacylglycerol, 
which in turn activates PKC synthesis [21], causing a number of effects, such as decreased synthesis of 
endothelial nitric oxide synthase and increased synthesis of endothelin-1, transforming growth factor β, 
plasminogen activator inhibitor-1 [22] and nuclear factor-κB (NF-κB) [23]. Ruboxistaurin, a specific inhibitor 
for the β-1 and -2 isoforms of PKC that are mostly activated in the diabetic retina, was developed and 
subjected to clinical trials. Although its use was associated with better visual acuity than placebo in patients 
with DME, and although there were remarkably few side effects, this interesting agent was not registered 
with an indication for treatment of DR [24]. 
 
 
Excess fructose-6-phosphate derived from high availability of intracellular glucose can be transformed to 
glucosamine-6-phosphate and then to uridine diphosphate N-acetylglucosamine, which acts on serine and 
threonine residues of transcription factors, resulting in pathological changes in gene expression [25]. 
 
 
Brownlee and co-workers have hypothesized that the possible common denominator (‘unifying 
mechanism’) of these apparently independent biochemical pathways is high-glucose-induced excess 
production of reactive oxygen species (ROS) by the mitochondrial electron transport chain inside the 
endothelium, as a result of increased flux through the Krebs cycle [16,23]. ROS, by causing strand breaks in 
nuclear DNA, activate poly-(ADP-ribose) polymerase (PARP), which in turn inhibit GAPDH activity [26], 
therefore pushing metabolites from glycolysis in the upstream pathways mentioned above. 
 
 
Benfotiamine, a thiamine derivative which can be administered orally, blocks all the above major pathways 
implicated in the pathogenesis of DR, and has been shown effective in preventing experimental DR [27]. 
However, clinical trials showing its effectiveness are still lacking. 
 
Current Treatment Options 
 
Current possibilities to prevent and/or treat retinopathy include optimized control of blood glucose and 
blood pressure and screening for early identification of high-risk, although still asymptomatic, retinopathy. 
 
 
The Diabetes Control and Complications Trial (DCCT) showed in patients with type 1 diabetes that 
optimized insulin treatment reduces the incidence of retinopathy by 76%, progression of mild-to-moderate 
non-PDR by 54% and the need for photocoagulation by 56% [28]. In patients with type 2 diabetes, the UK 
Prospective Diabetes Study (UKPDS) showed that, over 12 years, optimized metabolic control reduces 
progression of DR by 21% and the need for cataract surgery in 24% of the cases [29]. Follow-up of the 
patients involved in these studies showed that the beneficial effects of glycaemic control carry over in time 
in a sort of metabolic ‘memory’[30] or ‘legacy’[31], so that any period of life spent in good glycaemic 
control is ‘accounted for’ in the later prevention of retinopathy and other complications. 
  
The UKPDS [32] also showed that reducing blood pressure (from 154/87 to 144/82 mmHg throughout 8 
years) reduces the progression of DR by 34% and the overall risk of worsening of visual acuity by 47%, 
possibly by reducing DME. Until recently, the only intervention study to support a role for intensive 
hypertension control in the prevention of DR was the UKPDS. However, the Action in Diabetes and VAscular 
disease preterax and diamicroN mr Controlled Evaluation (ADVANCE) [33] and ACtion to COntrol 
cardiovascular Risk in Diabetes (ACCORD) [34] trials could not confirm an influence of blood pressure 
lowering on progression of DR. However, the patients in the UKPDS had larger reductions from higher 
blood pressure values than those in ADVANCE (−5.6 mmHg systolic pressure and −2.2 diastolic blood 
pressure from 145/81 mmHg, follow-up 4.3 years) [33] or in ACCORD, starting from 135/75 down to 128/68 
with a median follow-up of 3.7 years [34], suggesting either that blood pressure lowering is more effective 
in poorly controlled hypertension or that longer follow-up is necessary to observe an effect on DR 
progression. No legacy effect was observed for blood pressure control in the UKPDS patients [31]. 
 
 
Current guidelines recommend to maintain glycated haemoglobin (HbA1c) below 7.0% and blood pressure 
below 130/80. However, achieving these targets is far from easy outside of clinical trials in the general 
diabetic population and data collected in the USA [35], France [36], UK [37], Italy [38] and other countries 
show that less than half, often less than one third, of patients do stay within those targets. Patients on 
insulin therapy have worse control than those treated with oral hypoglycaemic agents and, in turn, the 
latter fare worse than those on diet alone [37], presumably reflecting the levels of residual endogenous 
insulin secretion. Possible reasons for this high level of therapeutic failure include medical inertia, reduced 
patient adherence to prescriptions and the inadequacy of current pharmacological options and lifestyle 
measures. 
 
 
Doctors often are poorly proactive in correcting high levels of HbA1c and blood pressure, as shown by a 
survey of practice in 30 American academic clinics [35]. That however may not be the only reason. In a 2-
year clinical intervention study conducted in Liverpool on 200 patients with inadequate metabolic control, 
the best efforts of doctors went unrewarded and the only patients who obtained a drop in HbA1c were 
those treated with diet only [37]. The situation is particularly worrying in children and adolescents among 
whom, according to a recent report, less than 5% have an HbA1c lower than 7.0% and more than 80% are 
above 8.0% [39]. It may be that therapeutic goals are too ambitious, at least for younger and older age 
groups, as suggested for the latter by an increase in mortality observed when trying to push the HbA1c 
target below 6.5% [40]. It is also possible that individual patients are somehow set on different levels of 
diabetes severity, manifested by their values of HbA1c, in different stages of their life. Of course, this is a 
point of view that can be perceived as pragmatic or utilitarian, perhaps politically incorrect and certainly 
not supported by scientific evidence. However, if one considers goal focusing and personal motivation as 
contributors to improve metabolic control, then it stands out that only in exceptional circumstances of 
limited duration, such as pregnancy, are levels of HbA1c below 6.5% reached in more than 80% of patients 
[41], often to drift back upwards after delivery. 
 
 
In any case, the overall outcomes of diabetes care seem to be improving gradually worldwide, thanks to 
increasing awareness and availability of materials for self-monitoring and therapy. Data from the National 
Health and Nutrition Examining Survey (NHANES) 1999–2004 show a slow but steady increase in the 
percentage of US patients with HbA1c < 7.0% [42]. Probably in connection with this positive trend, the 
epidemiological data collected in Scandinavia and Wisconsin show a lower cumulative incidence of 
proliferative retinopathy in patients who contracted type 1 diabetes in more recent years [43,44]. In the 
DCCT/Epidemiology of Diabetes Interventions and Complications (EDIC) cohort, in 30 years of follow-up, 
the cumulative incidence of PDR was 21% in the patients originally randomized to optimized therapy during 
the DCCT, compared to 50% in those who remained all their life on conventional treatment [30]. 
 
 
There are, however, different approaches to interpreting these data. Progression of DR might be delayed 
rather than reduced in absolute terms, and the prolongation of life expectancy in patients may result in 
PDR appearing later rather than never at all. Data extrapolated from the DCCT dataset suggest that 
optimized insulin treatment would prolong life free of PDR by 14.7 years, of macular oedema by 8.2 years 
and life free of blindness by 7.7 years [45], all weighted against a two to three times higher risk of severe 
hypoglycaemia and increase in body weight. In addition, other predisposing factors not yet identified may 
play a role, as suggested by daily clinical experience and also quantified in the DCCT series. In fact, a post 
hoc analysis of all patients who participated in the trial showed that 10% of those who remained in the 
lowest HbA1c quintile (<6.87%) still developed DR, and 43% of those who remained in the worst quintile 
(HbA1c > 9.49%) did not develop retinal lesions during the study [46]. The search for genetic markers that 
make patients susceptible to, or protected by, microangiopathy remains an open field that has so far 
produced few generalizable results. 
 
 
Currently, the main therapeutic tool at our disposal to prevent visual impairment consequent to DR is laser 
photocoagulation, which reduces the incidence of blindness from PDR by 95% and loss of visual acuity due 
to DME by 50% [47]. When laser is not sufficient, because retinopathy is too advanced and/or aggressive, 
vitreoretinal surgery (vitrectomy) becomes an option [48]. 
 
 
As blood glucose and blood pressure levels recommended by the guidelines cannot be reached in all 
patients, and as retinopathy may still develop in patients who are well controlled, it is paramount to 
organize systematic population screening programmes. Screening is a simple diagnostic procedure applied 
to an entire population at risk aimed at identifying severe lesions that can be subjected to appropriate 
treatment before they have caused symptoms and functional damage. Screening does not represent a 
complete diagnostic workup but a method to identify patients who require further investigation. The 
efficacy of screening for high-risk DR has been shown in places such as Iceland or Sweden, where it has led 
to the reduction of diabetes-related blindness [49]. A countrywide screening programme has been 
established in the UK [50], and the results will become available in the coming years. 
 
 
New Therapeutic Perspectives 
 
Lack of therapies targeting specific pathogenetic mechanisms remains a serious limitation to the prevention 
of diabetes-related blindness. Experimental evidence suggests involvement of the renin-angiotensin system 
(RAS) in that a physiologically active RAS is present in the eye, where angiotensin-2 appears to promote 
retinal expression of vascular endothelial growth factor (VEGF), through AT-1 receptors, and endothelial 
cell proliferation. 
 
 
The EUrodiab Controlled trial of Lisinopril in Insulin-dependent Diabetes mellitus (EUCLID) study [51] 
reported that lisinopril, an angiotensin-converting enzyme inhibitor (ACEi), may reduce the progression of 
DR and the incidence of PDR in patients with type 1 diabetes. However, retinopathy was not a primary 
outcome of the study, which was also undersized from the statistical power point of view. The more recent 
ADVANCE/ADvance REtinal Measurements (ADREM) [52] appeared to show some protective effect, 
although not statistically significant, on progression of retinopathy of another ACEi, perindopril, associated 
with indapamide, a diuretic, in 1241 patients with type 2 diabetes. DIRECT (Diabetic Retinopathy 
Candesartan Trials) was a group of three multicentre, randomized, placebo-controlled studies designed to 
determine if the pharmacological blockade of the RAS by 32 mg of candesartan is able to prevent the onset 
of DR in patients with type 1 diabetes (DIRECT-Prevent 1) and to prevent progression or promote 
regression of DR in patients with type 1 (DIRECT-Protect 1) and 2 (DIRECT-Protect 2) diabetes [53,54]. A 
total of 5231 patients with normoalbuminuria were randomized. All patients with type 1 diabetes and 27% 
of those with type 2 diabetes were normotensive, while the remainder were taking non-RAS blockers for 
hypertension. The average follow-up was 4.7 years. Prevent-1 showed that candesartan reduces the risk of 
onset of retinopathy in type 1 diabetes by 35%, with an NNT of 18 patients treated to prevent one event. 
The severity of retinopathy at the end of the study was significantly more favourable in patients treated 
with candesartan in Prevent-1, Protect-1 [53] and Protect-2 [54]. The latter study showed a 13% reduction, 
not statistically significant, in the risk of progression of DR and a highly significant 34% increase in the 
probability of DR regression in type 2 diabetes, with Numbers Needed to Treat (NNT) of 21 patients treated 
to achieve an event. The results of DIRECT-Protect 2 represent the first description in the literature of 
regression of DR induced by a drug. The favourable effect of RAS blockade was confirmed by the Renin 
Angiotensin System Study (RASS) [55], conducted on 285 normotensive patients treated with 20 mg/day 
enalapril, 100 mg/day losartan or placebo. Enalapril and losartan reduced the likelihood of DR progression 
by 65 and 70%, respectively, in patients with type 1 diabetes. Although the results of the previous studies 
are strongly indicative of a beneficial effect of RAS blockade in the early stages of DR, none of them was 
sufficient to grant registration for this specific indication. Hence, their use cannot be formally 
recommended in patients with DR who do not also have hypertension and/or microalbuminuria. 
With reference to other possible mechanisms, the FIELD study showed a reduction by approximately 30% in 
the need for laser treatment for DME and PDR in patients treated with 200 mg/day fenofibrate. The drug 
prevented progression of existing retinopathy, regardless of its metabolic effects, but was not effective in 
terms of primary prevention [56]. Moreover, the retinopathy endpoint was a tertiary objective, measured 
in 1012 of 9795 patients enroled in the study. Another clinical trial, ACCORD [34], confirmed reduced 
progression of DR in patients with type 2 diabetes treated with fenofibrate and statins, compared to 
patients treated with statins alone. The possible mechanisms for this unexpected action of fenofibrate 
remain to be elucidated. 
 
 
Increased tendency to platelet aggregation in diabetes has long been suspected to play a role in 
determining capillary occlusions, which characterize the intermediate stages of non-P DR. Antiplatelet 
drugs such as aspirin, dipyridamole and ticlopidine underwent clinical trials in the 1970s and 1980s, 
showing modest efficacy in slowing the formation of new microaneurysms in early non-PDR [57,58] and no 
effects on evolution once DR reaches the preproliferative and proliferative stages [59]. Aspirin, however, 
does not increase the risk of bleeding from new vessels, so that proliferative retinopathy is not a 
contraindication to its use for other indications [59]. 
 
 
The only example of an effective mechanism-targeting treatment in DR is the use of anti-VEGF agents in 
DME. VEGF is upregulated in eyes with DME [60] and may be a major mediator of increased retinal 
permeability [61]. Anti-VEGF agents have to be injected directly into the vitreous body at regular intervals. 
Those under more advanced investigation include bevacizumab, ranibizumab and pegaptanib. While laser 
treatment permits at best to preserve visual acuity, clinical trials indicate that vision can improve with 
repeated injections of 1.25 mg bevacizumab [62], 0.5 mg ranibizumab [63] and 0.3 mg pegaptanib [64]. 
Mean best-corrected visual acuity improvements of 4.7 letters are obtained with a mean of five injections 
over 36 weeks with 0.3 mg pegaptanib and 5.6 letters with a median of nine injections over 1 year with 
1.25 mg bevacizumab. VEGF Trap-Eye has also shown promising short-term results in a phase II study [65]. 
 
 
In addition, intravitreal triamcinolone has been widely used to treat DME and PDR in view of the 
inflammatory components in the pathogenesis of these sight-threatening stages of DR [66]. However, its 
benefits are short-lived, accompanied by high rates of cataract, glaucoma and infections, and the 3-year 
visual acuity is worse than obtained with grid laser treatment alone [67]. Visual acuity benefits of steroids 
are comparable to those of anti-VEGF in aphakic patients only [68]. 
 
  
Conclusions 
Overall, the results of the trials reported earlier suggest that interventions targeted at potential pathogenic 
mechanisms may be effective in early or mild, rather than moderate or more advanced stages of 
retinopathy in which damage to the capillary wall and the neuroretina may already be too advanced. Here, 
the question arises of whether a ‘point of no return’ exists in the natural history of DR. Antiplatelet agents 
appeared to slow down retinopathy at a very early stage characterized by the presence of microaneurysms 
alone [57,58], but not later when capillary occlusion becomes the prevailing feature [59]. Similarly, in 
DIRECT-Protect 2 [54], the administration of candesartan was associated with regression of minimal to mild 
retinopathy (occasional microaneurysms, microhaemorrhages, hard exudates and/or cotton wool spots), 
whereas non-proliferative stages, although classified as moderate, proved non-responsive, suggesting that 
also blockade of the RAS could be effective earlier than originally envisaged, again when damage of the 
capillary wall is minimal. This suggests that overactivation of the intraocular RAS may exert its pathogenic 
effects through mechanisms different from VEGF activation or that VEGF might have pathogenic effects 
independent of its ability to increase vessel wall permeability and angiogenesis, possibly involving its 
neuroprotective characteristics. However, data from FIELD [56] and ACCORD [34] appear to show that the 
progression of retinopathy can be stopped by fenofibrate at more advanced stages, moderate and severe 
non-proliferative, suggesting that different pathogenic mechanisms, responsive to different 
pharmacological agents, may intervene in various stages of this complication. 
 
 
Progress in medical treatment of DR remains incomplete, just like our understanding of the mechanisms 
underlying this complication. More is achieved in the advanced stages, using VEGF inhibitors, than early in 
the evolution of DR but we are still far from the day when retinopathy will be treated aiming directly at a 
cause (as we do, for example, with iron for iron-deficient anaemia) or a mechanism (as with proton pump 
inhibitors for peptic ulcers). Causes for failure so far to identify a primum movens for retinopathy and, 
more generally, diabetic microangiopathy involve a series of good reasons: lack of funding and researchers 
dedicated to the specific problem, a presumably multifactorial pathogenesis, and the undoubted 
complexity of the phenomena involved. It is hoped that, as diabetes and its complications rise worldwide, 
the mere health and economic size of its consequences will stimulate further research into this field of 
human disease. 
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